vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Enpro Inc. (NPO). Click either name above to swap in a different company.
Enpro Inc. is the larger business by last-quarter revenue ($295.4M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 14.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
ESPR vs NPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $295.4M |
| Net Profit | — | $-32.0M |
| Gross Margin | — | 42.1% |
| Operating Margin | 50.6% | 11.2% |
| Net Margin | — | -10.8% |
| Revenue YoY | 143.7% | 14.3% |
| Net Profit YoY | — | -330.2% |
| EPS (diluted) | $0.32 | $-1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $295.4M | ||
| Q3 25 | $87.3M | $286.6M | ||
| Q2 25 | $82.4M | $288.1M | ||
| Q1 25 | $65.0M | $273.2M | ||
| Q4 24 | $69.1M | $258.4M | ||
| Q3 24 | $51.6M | $260.9M | ||
| Q2 24 | $73.8M | $271.9M | ||
| Q1 24 | $137.7M | $257.5M |
| Q4 25 | — | $-32.0M | ||
| Q3 25 | $-31.3M | $21.6M | ||
| Q2 25 | $-12.7M | $26.4M | ||
| Q1 25 | $-40.5M | $24.5M | ||
| Q4 24 | — | $13.9M | ||
| Q3 24 | $-29.5M | $19.8M | ||
| Q2 24 | $-61.9M | $26.7M | ||
| Q1 24 | $61.0M | $12.5M |
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 50.6% | 11.2% | ||
| Q3 25 | -11.4% | 14.3% | ||
| Q2 25 | 8.6% | 15.9% | ||
| Q1 25 | -34.0% | 15.3% | ||
| Q4 24 | -6.4% | 12.5% | ||
| Q3 24 | -31.0% | 13.1% | ||
| Q2 24 | 3.5% | 17.7% | ||
| Q1 24 | 52.5% | 10.9% |
| Q4 25 | — | -10.8% | ||
| Q3 25 | -35.9% | 7.5% | ||
| Q2 25 | -15.4% | 9.2% | ||
| Q1 25 | -62.2% | 9.0% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | -57.2% | 7.6% | ||
| Q2 24 | -83.9% | 9.8% | ||
| Q1 24 | 44.3% | 4.9% |
| Q4 25 | $0.32 | $-1.50 | ||
| Q3 25 | $-0.16 | $1.01 | ||
| Q2 25 | $-0.06 | $1.25 | ||
| Q1 25 | $-0.21 | $1.15 | ||
| Q4 24 | $-0.14 | $0.65 | ||
| Q3 24 | $-0.15 | $0.94 | ||
| Q2 24 | $-0.33 | $1.27 | ||
| Q1 24 | $0.34 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $114.7M |
| Total DebtLower is stronger | — | $655.3M |
| Stockholders' EquityBook value | $-302.0M | $1.5B |
| Total Assets | $465.9M | $2.7B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $114.7M | ||
| Q3 25 | $92.4M | $132.9M | ||
| Q2 25 | $86.1M | $107.1M | ||
| Q1 25 | $114.6M | $240.3M | ||
| Q4 24 | $144.8M | $236.3M | ||
| Q3 24 | $144.7M | $206.9M | ||
| Q2 24 | $189.3M | $175.9M | ||
| Q1 24 | $226.6M | $163.9M |
| Q4 25 | — | $655.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $644.9M |
| Q4 25 | $-302.0M | $1.5B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.5B | ||
| Q1 25 | $-426.2M | $1.5B | ||
| Q4 24 | $-388.7M | $1.4B | ||
| Q3 24 | $-370.2M | $1.5B | ||
| Q2 24 | $-344.2M | $1.4B | ||
| Q1 24 | $-294.3M | $1.4B |
| Q4 25 | $465.9M | $2.7B | ||
| Q3 25 | $364.0M | $2.4B | ||
| Q2 25 | $347.1M | $2.4B | ||
| Q1 25 | $324.0M | $2.5B | ||
| Q4 24 | $343.8M | $2.5B | ||
| Q3 24 | $314.1M | $2.5B | ||
| Q2 24 | $352.3M | $2.5B | ||
| Q1 24 | $373.1M | $2.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 4.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $65.3M | ||
| Q2 25 | $-31.4M | $52.2M | ||
| Q1 25 | $-22.6M | $21.0M | ||
| Q4 24 | $-35.0M | $59.4M | ||
| Q3 24 | $-35.3M | $54.0M | ||
| Q2 24 | $-7.2M | $43.2M | ||
| Q1 24 | $53.8M | $6.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $53.4M | ||
| Q2 25 | — | $42.3M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $49.1M | ||
| Q3 24 | $-35.5M | $48.3M | ||
| Q2 24 | $-7.3M | $38.3M | ||
| Q1 24 | $53.8M | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 18.6% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 19.0% | ||
| Q3 24 | -68.7% | 18.5% | ||
| Q2 24 | -9.9% | 14.1% | ||
| Q1 24 | 39.0% | -0.7% |
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.3% | 2.2% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | — | 1.98× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | 0.88× | 0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
